oncnursingnews1h
Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.
oncnursingnews3d
Ann Culkin, RN, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3d
Katie Goodman, RN, BSN, CCRP
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Cancer Prevention Foundation
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
Dorothy N. Pierce
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5d
Donna L. Berry, PhD, RN, AOCN, FAAN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6d
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
oncnursingnews6d
Investigational Nasal Spray May Improve Symptoms in Cancer Cachexia
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
oncnursingnews6d
FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...
oncnursingnews6d
FDA Approves Datopotamab Deruxtecan for Advanced Breast Cancer
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer. The FDA granted approval to datopotamab ...